title: Role of IL-10 in the abnormalities of early cell activation events of lymphocytes from patients with systemic lupus erythematosus.
abstract: Lymphocytes from patients with systemic lupus erythematosus (SLE) exhibit abnormalities in early cell activation events as well as increased production of IL-10. We explored the possible role of IL-10 on defective cell activation events of SLE lymphocytes and first studied the in vitro effect of IL-10 on peripheral blood mononuclear cells (PBMNC) from healthy subjects. After 5 days of culture in the presence of exogenous IL-10, these cells demonstrated abnormal expression of CD69 as well as high intracellular pH and defective activation of the Na+/H+ anti-porter by PMA. We then investigated the effect of IL-10 blockade on PBMNC from SLE patients. SLE PBMNC cultured for 5 days with a blocking anti-IL-10 monoclonal antibody (mAb) partially corrected abnormalities in CD69 expression and intracellular pH; however, in 1/5 patients studied, no significant positive effect was observed. The effect of the anti-IL-10 mAb was apparently not related to protection against activation-induced cell death. We conclude that IL-10 in normal PBMNC induce some of the defects in early cell activation events seen in SLE lymphocytes. Accordingly, the blockade of IL-10 partially corrects these abnormalities in SLE cells. Our data further support the importance of IL-10 in immune dysfunction seen in SLE.
authors.affiliation: Department of Immunology, Facultad de Medicina, UASLP, San Luis Potosí, S.L.P., México. rgonzale@deimos.tc.uaslp.mx
authors.forename: R
authors.initials: R
authors.lastname: González-Amaro
authors.forename: D
authors.initials: D
authors.lastname: Portales-Pérez
authors.forename: L
authors.initials: L
authors.lastname: Baranda
authors.forename: C
authors.initials: C
authors.lastname: Abud-Mendoza
authors.forename: L
authors.initials: L
authors.lastname: Llorente
authors.forename: Y
authors.initials: Y
authors.lastname: Richaud-Patin
authors.forename: J
authors.initials: J
authors.lastname: Alcocer-Varela
authors.forename: D
authors.initials: D
authors.lastname: Alarcón-Segovia
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015703:Antigens, CD / Q000378:metabolism; D000945:Antigens, Differentiation, T-Lymphocyte / Q000378:metabolism; D016022:Case-Control Studies; D006801:Humans; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D016753:Interleukin-10 / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000494:pharmacology; D007424:Intracellular Fluid / Q000378:metabolism; D037181:Lectins, C-Type; D008180:Lupus Erythematosus, Systemic / Q000276:immunology* / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology*; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D011994:Recombinant Proteins / Q000494:pharmacology; D017923:Sodium-Hydrogen Exchangers / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D000099192:CD69 Antigens
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D016753:Interleukin-10; D037181:Lectins, C-Type; D011994:Recombinant Proteins; D017923:Sodium-Hydrogen Exchangers; D013755:Tetradecanoylphorbol Acetate; D000099192:CD69 Antigens